ADGRF2

Across TCGA pan-cancer cohorts, ADGRF2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADGRF2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADGRF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADGRF2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, SCLC, and SARC are the cancer types where ADGRF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.141	0.669	<.001	47	view →
SCLC	OS	Median	All	0.146	0.722	<.001	33	view →
SARC	DFS	Median	All	0.065	0.615	<.001	15	view →
LIHC	DFS	Median	All	0.029	0.545	<.001	15	view →
UCEC	DFS	Median	All	1.000	0.624	.007	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADGRF2–LUAD (OS)

Open the LUAD breakdown →